Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | RXRA | P19793 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | RARA | P10276 | 4/20 | 0.52 |
| ▸ | RARB | P10826 | 4/20 | 0.52 |
| ▸ | RARG | P13631 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.52 |
| ▸ | RXRG | P48443 | 2/20 | 0.52 |
| ▸ | RORC | P51449 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067470 | 1.00 | MAPT (0.72) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL4389190 | 0.89 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL17769829 | 0.89 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL7088911 | 0.89 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL4389183 | 0.89 | MAPT (0.76) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL13252674 | 0.88 | MAPT (0.64) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL5905823 | 0.88 | MAPT (0.74) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL11484869 | 0.87 | ALDH1A1 (0.54) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL1717832 | 0.86 | MAPT (0.71) | MAPTALOX15ALDH1A1RXRACYP3A4 | |
| SCHEMBL25378972 | 0.85 | MAPT (0.81) | MAPTALOX15ALDH1A1RXRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889660-B2 | Methods for treating obesity or an obesity related condition | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130072555-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-03-21 | — | — | US | disclosed |
| US-8338394-B2 | Methods for treating metabolic diseases | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100135977-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| US-20080249042-A1 | cultured prokaryotic or eukaryotic cell transformed or transfected with expression construct; vectors; treating retinal disease or blindness | UNIVERSITY OF WASHINGTON (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008063768-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1797176-A2 | ALL-TRANS-RETINOL : ALL-TRANS-13,14-DIHYDRORETINOL SATURASE AND METHODS OF ITS USE | University of Washington (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029398-A2 | ALL-TRANS-RETINOL : ALL-TRANS-13,14-DIHYDRORETINOL SATURASE AND METHODS OF ITS USE | UNIVERSITY OF WASHINGTON (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072555-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | GPR119, CYP27A1, HSD17B13 | MAPT 1214/4885ALOX15 89/4885ALDH1A1 480/4885 |
| US-20100135977-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | CYP27A1, HSD17B13, GPR119 | MAPT 847/4885ALOX15 107/4885ALDH1A1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.